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Abstract 
Background: With the improved overall survival (OS) of nasopharyngeal carcinoma (NPC) patients, the importance 
of quality of life (QoL) is increasingly being recognized. For some radiosensitive NPC patients, whether low‑dose radio‑
therapy can improve the QoL without affecting clinical efficacy is unknown. This study aimed to assess the survival 
rates and QoL of NPC patients treated with 50 Gy radiotherapy plus hematoporphyrin derivative (HPD).
Methods: Forty‑six newly diagnosed NPC patients treated with 50 Gy radiotherapy plus HPD between June 1988 
and July 1992 were analyzed. All patients were restaged according to the 7th edition of the American Joint Commit‑
tee on Cancer staging system. The radiotherapy plan was designed on the basis of pretreatment computed tomog‑
raphy. The OS, local recurrence‑free survival (LRFS), distant metastasis‑free survival (DMFS), and disease‑free survival 
(DFS) rates were estimated using the Kaplan–Meier method. QoL was assessed using the Late Radiation Morbidity 
Scoring Criteria of the Radiation Therapy Oncology Group.
Results: The 5‑year OS, LRFS, DMFS, and DFS rates were 74.3%, 72.6%, 82.1%, and 61.2%, respectively. The corre‑
sponding 10‑year rates were 38.4%, 62.9%, 78.5%, and 49.8%, respectively, and the 20‑year rates were 27.7%, 51.4%, 
78.5%, and 40.7%, respectively. None of the patients developed severe radiation‑related complications, such as 
radiation‑induced temporal lobe necrosis, hearing loss, trismus, and dysphagia.
Conclusion: Some NPC patients were sensitive to 50 Gy radiotherapy plus HPD, and this sensitivity was characterized 
by long‑term survival without significant late treatment morbidities.
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Background
Radiotherapy is a major treatment modality for naso-
pharyngeal carcinoma (NPC), and the 5-year survival rate 
is 66%–83% in NPC patients treated with radiotherapy 
alone [1–3]. The overall survival (OS) rates are greater 
than 90% for early-stage NPC patients [4, 5]. With the 
improved OS of NPC patients, the importance of quality 
of life (QoL) is increasingly being recognized. However, 
conventional definitive radiotherapy can lead to radiation-
related complications [6–10], such as xerostomia, trismus, 
hearing loss, neck fibrosis, and radiation-induced tempo-
ral lobe necrosis, which affect the QoL of NPC patients. 
The current radiotherapy for NPC is a “catch-all” therapy, 
wherein all NPC patients are given a prescribed radiation 
dose of approximately 60–70 Gy, covering a heterogene-
ous group of tumors that range from radiosensitive to 
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radioresistant. Thus, it is very important to improve the 
QoL of NPC patients without compromising the treat-
ment efficacy and to provide individualized radiotherapy 
according to different radiosensitivities of NPCs. In 2006, 
we divided NPCs into the following four types: radiosen-
sitive and non-metastasis-prone; radioresistant and non-
metastasis-prone; radiosensitive and metastasis-prone; 
and radioresistant and metastasis-prone [11]. This typ-
ing provides a new approach for NPC radiation planning 
based on the radiosensitivity and metastatic tendency. 
However, this typing approach is limited because it does 
not consider other doses below or above the conventional 
radiotherapy doses.
In clinical practice, a 56-year-old man was diagnosed 
with undifferentiated NPC at clinical stage IV (T2N3M0) 
according to the Chinese 1992 staging system and at 
stage IVb (T1N3M0) according to the 7th American 
Joint Committee on Cancer (AJCC) staging system. His 
treatment plan involved conventional radical radiation 
therapy; however, he did not complete the planned treat-
ment. As a result, the nasopharyngeal region was irradi-
ated with a total dose of 36 Gy, and the irradiation dose 
to the neck lymph node drainage region was 30.1  Gy. 
Afterwards, the patient did not receive any treatment. 
However, he lived cancer-free for an additional 10 years 
[12]. This case led us to wonder what type of nasopharyn-
geal tumors can be controlled with low-dose radiother-
apy and whether the case is generalizable. With these 
questions in mind, we retrospectively identified a series 
of NPC patients from the Sun Yat-sen University Cancer 
Center who were irradiated with only 50 Gy radiotherapy 
plus hematoporphyrin derivative (HPD) between June 
1988 and July 1992 and then analyzed their 20-year sur-
vival rates and QoL.
HPD is a complex mixture of porphyrins prepared 
from hematoporphyrin-IX (HP). Typically, this mixture 
consists of 20% HP, 20%–30% hydroxy-ethyl-vinyl-deu-
teroporphyrin, and 3%–5% protoporphyrin. The other 
half is a mixture of dimers, trimers, and some higher 
molecular weight oligomers. Under the background of 
researches which were conducted 20 years ago, HPD was 
assumed to be a radiosensitizer and can enhance the sen-
sitivity of some types of cancer cells to radiation [13, 14]. 
However, after more than 20  years of experience using 
HPD to treat tumors, recent studies showed that HPD 
was the most frequently used photosensitizer in photo-
dynamic therapy (PDT) [15, 16]. This therapy is based 
on the administration of a photosensitizer followed by 
localized exposure of the target tissue to laser-generated 
light. Light is absorbed by the photosensitizer, which sub-
sequently initiates the photo-chemical reaction to form 
cytotoxic agents within the irradiated field to kill neo-
plastic cells [17]. The photoexcitation of HPD generates 
singlet oxygen, which is suggested as the main damaging 
agent in PDT. HPD is a photosensitizer, not a radiosensi-
tizer, and it works by laser rather than X-ray used in radi-
otherapy. Thus, HPD can’t enhance the radiosensitivity of 
nasopharyngeal cancer cells. Therefore, in this study, we 
don’t introduce too much about the role of HPD in the 
survival rates and QoL of NPC patients treated with low-
dose radiotherapy plus HPD. This study analyzed the sur-




The present study was on the basis of a clinical trial enti-
tled “The optimal regimen of comprehensive treatment 
for nasopharyngeal carcinoma” (Grant No. 85-914-02) 
[18]. The patient inclusion criteria of that trial were as 
follows: (1) histological diagnosis of NPC; (2) no prior 
treatment before radiotherapy; (3) no distant metastases; 
and (4) Eastern Cooperative Oncology Group (ECOG)/
World Health Organization (WHO)/Zubrod perfor-
mance score less than four. The exclusion criteria were 
any of the following: (1) distant metastases; (2) presence 
of other malignancies; and (3) severe complications or 
active infection. The institutional review board approved 
the protocol, and all patients provided written informed 
consent for participation.
All patients underwent a pre-treatment evaluation that 
included a complete physical examination, fiberoptic 
nasopharyngoscopy, computed tomography (CT) scan-
ning of the nasopharynx and neck, chest radiography, 
and abdominal sonography. The Chinese 1992 staging 
system [19] was used for stage classification. A total of 
144 patients were enrolled in the previous study: 49 were 
given radiation treatment alone, and 95 were given HPD 
plus radiation treatment (Fig. 1). The patients in the lat-
ter group were divided into two subgroups according to 
their CT evaluation after receiving 50 Gy radiotherapy. If 
the CT evaluation showed a partial response, the primary 
tumor was irradiated with additional 10–20 Gy. If the CT 
evaluation showed a complete response, radiotherapy was 
stopped at 50  Gy. In the HPD plus radiation treatment 
group, 46 patients showed complete response after 50 Gy 
of radiation. Therefore, the 46 NPC patients were selected 
in this study and the 20-year follow-up data of them were 
analyzed in the present study. All patients were restaged 
according to the 7th edition of the AJCC staging system.
Radiotherapy
All patients were given 50 Gy conventional external beam 
radiotherapy plus HPD. A daily fraction of 2 Gy and five 
fractions per week were delivered using a cobalt-60 or lin-
ear accelerator. Opposing lateral faciocervical fields were 
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used in the two-dimensional conformal radiotherapy 
to cover the nasopharynx and upper cervical lymphatic 
drainage region, with one lower anterior cervical field to 
cover the lower cervical region. After 40  Gy, opposing 
lateral preauricular fields were used to cover the primary 
region and anterior split neck fields were used to cover 
the cervical region. The total dose to the primary tumor 
was 50  Gy, and the total dose to the lymph drainage 
region was 40–50  Gy. Treatment was completed within 
5 weeks.
Assessment of QoL
The QoL of NPC patients was assessed according to the 
functional assessment of cancer therapy-head and neck 
(FACT-H&N) V4 [20, 21] and the Radiation Therapy 
Oncology Group (RTOG) CTC3.0 radiation morbidity 
grading system [22]. These QoL measures included the 
following seven items: neck skin, hearing loss, dry mouth, 
brain injury, distance between two dens incisivus media-
lis, sleep, and appetite. Scores ranged from 0 to 4; a high 
score represented a relatively poor QoL.
Follow‑up and statistical analysis
In the first 3  years after radiotherapy, the patients were 
followed up every 3 months. After 3 years, the follow-up 
intervals gradually increased from 6  months to 1  year. 
Follow-up was performed by outpatient review, tel-
ephone, or letters. The routine examinations included a 
complete physical examination, nasopharyngeal endos-
copy, blood and biochemistry profiles, chest radiography, 
abdominal ultrasonography, and CT/magnetic resonance 
image (MRI) scans of the nasopharynx and cervical 
region. CT scans of the abdominopelvic cavity or chest, 
bone scans, and positron emission tomography scans 
were performed only in symptomatic patients. Patients 
without recent examination tests in the medical records 
were followed up by telephone calls. Patients who were 
lost to follow-up were censored at the last time of con-
tact. Nine patients were lost to follow-up, and the fol-
low-up rate was 80.4%. All endpoints were defined from 
the starting date of radiotherapy to the date of an event 
occurrence or the last follow-up.
The statistical analysis was performed using SPSS ver-
sion 16.0 software (SPSS, Chicago, IL, USA). The actuar-
ial rates were calculated using the Kaplan–Meier method, 
and the differences were compared using the log-rank 
test. P values less than 0.05 were considered significant.
Results
Patient characteristics
The clinical characteristics of the 46 patients are listed 
in Table  1. Among the patients, 31 were men and 15 
were women, with a ratio of 2.07:1. The median age was 
43  years (range 26–67  years). Pathologic examinations 
showed that 43 patients had poorly differentiated squa-
mous cell carcinoma, and three had highly differentiated 
squamous cell carcinoma.
Follow‑up outcomes
The final follow-up was performed in August 2012, and 
the median follow-up duration was 99  months (range 
9–250  months). A total of 42 patients were followed 
beyond 10  years. Nine patients were lost to follow-up: 
three were lost within 3  years after the completion of 
50 Gy + HPD
(n = 95)
60-70 Gy RT alone 
(n = 49)
CT









Fig. 1 Flow chart of nasopharyngeal carcinoma (NPC) patient selection. RT radiotherapy; HPD hematoporphyrin derivatives; CT computed tomog‑
raphy; PR partial response; CR complete response
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radiotherapy, and five were lost 10  years after radio-
therapy. Of the 46 patients, 42 (91.3%), 42 (91.3%), and 
39 (84.8%) had complete follow-up data available at 5, 10, 
and 20 years, respectively. During follow-up, 30 patients 
died: 11 died of recurrence, eight died of distant metasta-
sis, and 12 died of other causes (Table 2).
Survival rates
The 5-year OS, local recurrence-free survival (LRFS), dis-
tant metastasis-free survival (DMFS), and disease-free 
survival (DFS) rates were 74.3%, 72.6%, 82.1%, and 61.2%, 
respectively. The corresponding 10-year rates were 38.4%, 
62.9%, 78.5%, and 49.8%, respectively, and the 20-year 
rates were 27.7%, 51.4%, 78.5%, and 40.7%, respectively 
(Fig. 2). The 5-, 10-, and 20-year survival rates of patients 
at different clinical stages, as well as the T and N stages, 
are summarized in Table 3.
QoL results
The acute and late radiation toxicity data are reported 
in Table  4. Most acute toxicities were mild. The major 
grades 3–4 acute toxicities were mucositis (21.7%) and 
dermatitis (13.0%).
The occurrence rates of grades 1 and 2 late toxicities 
were 90.5% and 2.4% for xerostomia and 83.3% and 4.8% 
for hearing loss, respectively, for the 42 patients who 
were followed up for at least 10  years. Additionally, of 
the nine patients who survived for no less than 20 years, 
none had grade 2 or more severe late complications, 
two suffered from grade 1 restriction of mouth open-
ing, and six had grade 1 xerostomia and hearing impair-
ment. Temporal lobe necrosis, cranial nerve palsy, optic 
nerve/chiasm injury, brainstem injury, hypopituitarism, 
and hypothyroidism were not observed in any patient. 
Figure  3 shows the whole body bone scan, head and 
neck MRI, and chest and abdominal CT scan of a NPC 
patient who survived for 20 years after 50 Gy radiother-
apy plus HPD. Her physical and imaging examinations 
were all normal, and she had a good QoL without any 
late complications.
Discussion
In this study, we report on the long-term survival and 
low occurrence rates of late toxicities for some radio-
sensitive NPC patients after they received 50 Gy radio-
therapy plus HPD. In our study, for the 46 NPC patients 
who were treated with 50  Gy radiotherapy plus HPD 
20  years ago, the 5-, 10- and 20-year DFS rates were 
61.2%, 49.8%, and 40.7%, respectively. Our results 
were close to those reported by Yi et  al. [1], who ana-
lyzed patients treated with 70–72  Gy between 1990 
and 1999 with 5- and 10-year DFS rates of 58.4% and 
52.1%, respectively. Because of the relatively small sam-
ple size in our study and heterogeneity of the involved 
population, the survival rates in our study may not be 
representative, but we have at least confirmed that some 
radiosensitive NPC patients can be treated with 50 Gy 
radiation. The 46 NPC patients received HPD during 
the course of radiotherapy to enhance radiosensitiv-
ity. However, recent studies have shown that HPD can’t 
Table 1 Clinical characteristics of  the 46 patients 
with nasopharyngeal carcinoma (NPC)
T tumor; N node
a  According to the 7th American Joint Committee on Cancer (AJCC) staging 
system for NPC
Characteristic No. of patients Percentage (%)
Age (years)
 ≤45 26 56.5
 >45 20 43.5
Gender
 Male 31 67.4
 Female 15 32.6
Clinical stagea
 I 3 6.5
 II 13 28.3
 III 23 50.0
 IV 7 15.2
T stagea
 T1 8 15.2
 T2 9 26.1
 T3 22 43.5
 T4 7 15.2
N stagea
 N0 12 26.1
 N1 27 50.0
 N2 6 21.7
 N3 1 2.2
Histology
 Poorly differentiated 43 93.5
 Well differentiated 3 6.5





Recurrence alone 10 21.7
Nasopharynx 2 4.3
Cervical lymph nodes 4 8.7
Nasopharyngeal and cervical lymph nodes 4 8.7
Distant metastasis alone 7 15.2
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function as a radiosensitizer for the radiation treatment 
of cancer [15, 16]. Therefore, it cannot affect the efficacy 
of radiotherapy.
It is worth mentioning that none of the NPC patients 
in our study received chemotherapy. Chemotherapy also 
plays an important role in improving patients’ survival 
[23–25], which may explain the relatively low 5-year 
LRFS rate (72.6%) in our study. Additionally, our study is 
based on a two-dimensional technique. For two-dimen-
sional radiotherapy, the target volume coverage and nor-
mal tissue sparing are not well balanced. By contrast, 
intensity-modulated radiation therapy (IMRT) offers 
excellent target volume coverage and protects the nor-
mal tissue adjacent to the target [26]. Several studies have 
reported that the use of IMRT had improved the 5-year 
LRFS rate of patients with non-metastatic NPC from 
84% to 93% and had reduced late toxicity as compared 
with conventional radiotherapy [27, 28]. Thus, if we use 
chemotherapy combined with low-dose IMRT to treat 
radiosensitive NPC patients, we can significantly improve 
both the survival rate and QoL, making the prospect 
of low-dose radiotherapy for radiosensitive NPC more 
promising.
Radiotherapy has an important role in treating NPC, 
but there is major controversy in high-dose conven-
tional radiotherapy concerning severe late toxicities 
and high incidence of radiation-related toxicities. 
The radiation-induced complications affect the QoL 
Fig. 2 The Kaplan–Meier estimated survival curves of the 46 patients with NPC. a overall survival; b local recurrence‑free survival; c distant 
metastasis‑free survival; and d disease‑free survival
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of NPC patients, especially for pediatric and adoles-
cent NPC patients. Using radiation at doses between 
66 and 80 Gy, many researchers have reported occur-
rence rates of 42.3%–98% for xerostomia [2, 9, 29, 
30], 5%–66% for restriction of mouth opening [2, 7, 
9, 30, 31], 4.5%–58% for neck fibrosis [2, 7, 9, 29, 30], 
and 1%–6% for radiation-induced brain necrosis [2, 6, 
32]. In our study, there was a moderate incidence of 
acute toxicities; all patients demonstrated good com-
pliance and successfully completed radiation on the 
basis of supportive treatment. Of the patients who 
survived no less than 20  years after receiving 50  Gy 
radiotherapy, severe radiation-related complications 
were rarely observed. Six patients (66.7%) developed 
grade 1 xerostomia and ototoxicity, 2 (22.2%) devel-
oped grade 1 restriction of mouth opening, and none 
developed grade 3–4 toxicities. All survival patients 
had a good QoL. The rate of radiation-induced com-
plications was lower in patients who received 50  Gy 
radiotherapy than in those who received high-dose 
radiation. One possible explanation is that the normal 
tissue adjacent to the target received a lower radiation 
dose in the 50  Gy group. Furthermore, these patients 
may have better tolerance of radiation toxicities as 
they lived longer and repaired normal tissue. There-
fore, compared with conventional radiotherapy, 50 Gy 
radiotherapy has a distinct advantage in improving the 
QoL of NPC patients.
A major challenge that we face is to identify radio-
sensitive NPC patients. Many studies have reported 
predictive markers for radiosensitivity [33–39]. We also 
have proposed some markers for identifying radiosen-
sitive NPC, such as DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) protein and breast can-
cer susceptibility gene (BRCA) 1/BRCA2-containing 
complex, subunit three (BRCC3) [40, 41]. However, 
the detection of these sophisticated indictors is dif-
ficult in practice due to the restrictions in the current 
diagnostic and treatment techniques. Hence, a radio-
sensitivity categorization system with a delicate bal-
ance of accuracy and practicality should be considered. 
Additionally, further studies are needed to identify the 
target patients and provide individualized radiation 
treatment.
Our study has several limitations. First, 20  years is a 
long follow-up time; because of the changes in the resi-
dential addresses and contact information, the rate of 
follow-up is not sufficiently high and our findings are 
incomplete. Second, the cohort was selected from a spe-
cific, regionally based population that may not be rep-
resentative of the general population of NPC patients. 
Third, the limited sample size and low numbers of posi-
tive events in our study could be a potential source of 
bias. Fourth, 85% of the patients had stages I-III NPC in 
this study, which may be explained by that small tumors 
do not require high radiation doses for tumor control 
because of the log-cell-kill principle of radiation treat-
ment. However, we failed to compare small versus large 
tumors in our analysis due to the small sample size. The 
association of clinical stage with the radiosensitivity of 
NPC should be further assessed. Fifth, the patients were 
treated with radiotherapy plus HPD. Although HPD 
doesn’t affect radiosensitivity, it has exhibited an anti-
proliferative effect on various human cancer cells in pho-
todynamic therapy [42, 43], and its role in the treatment 
of NPC requires further investigation. Finally, identify-
ing radiosensitive NPC patients is still a problem that 
requires further investigation, and we should be cautious 
about using low-dose radiotherapy to treat NPC. For 
these reasons, we must validate our findings in a larger 
sample of patients with a multi-institutional prospective 
study design.
Table 4 Acute and  late toxicities in  the 46 NPC patients 
treated with  50  Gy radiotherapy plus  hematoporphyrin 
derivative
All values are presented as the numbers of patients followed by percentages in 
the parentheses
a  The 42 patients who were followed up for at least 10 years are included in the 
analysis of late toxicities
Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Acute toxicities
 Skin (dermatitis) 0 32 (69.6) 8 (17.4) 6 (13.0) 0
 Mucositis 0 16 (34.8) 20 (43.5) 10 (21.7) 0
 Xerostomia 0 33 (71.7) 13 (28.3) 0 0
 Hearing loss 40 (87.0) 6 (13.0) 0 0 0
Late toxicitiesa
 Temporal lobe 
necrosis
42 (100) 0 0 0 0
 Cranial nerve palsy 42 (100) 0 0 0 0
 Optic nerve/chiasm 
injury
42 (100) 0 0 0 0
 Brainstem injury 42 (100) 0 0 0 0
 Hypopituitarism 42 (100) 0 0 0 0
 Hypothyroidism 42 (100) 0 0 0 0
 Trismus 35 (83.3) 7 (16.7) 0 0 0
 Neck fibrosis 36 (85.7) 6 (14.3) 0 0 0
 Xerostomia 3 (7.1) 38 (90.5) 1 (2.4) 0 0
 Hearing loss 5 (11.9) 35 (83.3) 2 (4.8) 0 0
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Conclusion
In a subset of radiosensitive NPC patients, 50 Gy radio-
therapy conferred a high long-term survival rate and 
good QoL.
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Fig. 3 Examination of an NPC patient 20 years after 50 Gy radiotherapy plus HPD. a whole body bone scan image without abnormally increased 
uptake; b nasopharyngeal neoplasm disappears on nasopharyngeal magnetic resonance image (MRI); c cervical lymph node metastases are not 
found on cervical MRI; d chest computed tomography (CT) is normal; e upper abdominal CT without any abnormal lesion; f metastases are not 
found on lower abdominal CT
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